Drug intelligence / Profile preview

KL-7SHRNA

Development stage: Phase 1
Lead developer: Guangdong Medical University
Modality: Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
Administration: Intravenous

Overview

KL-7SHRNA is a gene therapy treatment involving 7shRNA lentiviral vector transduced CD34+ hematopoietic stem cell transplantation. It is being studied for the treatment of patients with HIV-1 infection (AIDS) combined with lymphoma. The treatment process involves administering chemotherapy before stem cell transplant, followed by mobilization and collection of CD34+ hematopoietic stem cells from the patient's peripheral blood. These stem cells are then isolated, transduced with the lenti-7shRNA vector, and reinfused to replace blood-forming cells destroyed by chemotherapy.

Other names: 7shRNA lentiviral vectorlenti-7shRNAlenti7shRNAlenti 7shRNA

Targets

HIV-1 RNA (HIV-1 RNA genome)

Beyond the preview

Go deeper on KL-7SHRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KL-7SHRNA.

Explore the full profile